Search

Search Constraints

You searched for: Author/Creator Justice, Robert

Search Results

1. Assessment of benefits and risks in development of targeted therapies for cancer — The view of regulatory authorities. Issue 5 (16th October 2014)

4. Pain palliation measurement in cancer clinical trials: The US Food and Drug Administration perspective. Issue 5 (5th December 2013)

5. Pain palliation measurement in cancer clinical trials: The US Food and Drug Administration perspective. Issue 5 (5th December 2013)

6. Reply to Letter to the Editor: Local Evaluation and Blinded Central Review Comparison a Victim of Meta-analysis Shortcomings. (March 2014)

7. U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations. (27th May 2014)

8. U.S. Food and Drug Administration Approval Summary: Erlotinib for the First‐Line Treatment of Metastatic Non‐Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations. (27th May 2014)